These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3425579)

  • 1. Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide.
    Thompson IM; Spence CR; Lamm DL; DiLuzio NR
    Am J Med Sci; 1987 Nov; 294(5):294-300. PubMed ID: 3425579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synergistic effect of hyperthermia and chemotherapy on murine transitional cell carcinoma.
    Haas GP; Klugo RC; Hetzel FW; Barton EE; Cerny JC
    J Urol; 1984 Oct; 132(4):828-33. PubMed ID: 6540817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of polyribonucleotides for mouse transitional cell carcinoma enhanced by cyclophosphamide.
    Borden EC; Sidky YA; Groveman DS; Bryan GT
    Cancer Res; 1985 Jan; 45(1):45-50. PubMed ID: 3965150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 2 suppression of a murine bladder cancer implanted into kidney, bladder and skin; its organ specificity.
    Lee KE; O'Donnell RW; Weiss GH; Cockett AT
    J Urol; 1988 Oct; 140(4):840-3. PubMed ID: 3262172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunochemotherapy for murine bladder tumor with a new human recombinant tumor necrosis factor (rTNF-S), VP-16 and hyperthermia.
    Iizumi T; Yazaki T; Waku M; Soma G
    J Urol; 1989 Aug; 142(2 Pt 1):386-9. PubMed ID: 2746758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of tumors to biologic modifiers and chemotherapeutic agents.
    Katsuoka Y; deKernion JB
    Tokai J Exp Clin Med; 1983 May; 8(2):175-85. PubMed ID: 6658848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
    Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
    Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical and systemic chemotherapy of murine bladder cancer.
    Soloway MS
    Cancer Res; 1977 Aug; 37(8 Pt 2):2918-29. PubMed ID: 406041
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes in lymphocyte subsets following administration of interleukin 2 and cyclophosphamide in mice with transitional cell carcinoma.
    Ikemoto S; Kamizuru M; Wada S; Asai Y; Kishimoto T
    Oncol Res; 1997; 9(2):71-5. PubMed ID: 9167188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination radiotherapy and chemotherapy in murine bladder cancer.
    Weldon TE; Kursh E; Novak LJ; Persky L
    Urology; 1979 Jul; 14(1):47 52. PubMed ID: 452220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer.
    Soloway MS
    Natl Cancer Inst Monogr; 1978 Dec; (49):327-32. PubMed ID: 748788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allium sativum (garlic) treatment for murine transitional cell carcinoma.
    Riggs DR; DeHaven JI; Lamm DL
    Cancer; 1997 May; 79(10):1987-94. PubMed ID: 9149027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chemoimmunotherapy with and without surgery in murine MBT-2 bladder tumor.
    Tzai TS; Lin JS; Chow NH
    Urol Int; 1994; 53(1):6-11. PubMed ID: 7974890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keyhole-limpet haemacyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma.
    Lamm DL; Reyna JA; Reichert DF
    Urol Res; 1981; 9(5):227-30. PubMed ID: 7303346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined effect of interleukin 2 and cyclophosphamide in therapy of mice with transitional cell carcinoma.
    Ikemoto S; Kamizuru M; Wada S; Hayahara N; Nishio S; Kishimoto T; Maekawa M
    Urology; 1992 Dec; 40(6):574-8. PubMed ID: 1466115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy of experimental transitional-cell carcinoma.
    DeKernion JB; Soloway MS; Persky L
    Urology; 1974 Jul; 4(1):63-8. PubMed ID: 21322986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific immunotherapy of murine bladder cancer with butanol-extracted antigens and ethylchlorformate polymerized tumor protein.
    Rochester MG; Sarosdy MF; Pickett SH; Stogdill BJ; Lamm DL
    J Urol; 1988 Sep; 140(3):647-50. PubMed ID: 3411695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A murine model for bladder cancer.
    Murphy GP; Sandberg AA; Pontes JE; Ochi H; Yoshida M; Williams PD
    Prog Clin Biol Res; 1984; 162A():177-200. PubMed ID: 6541340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.